<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074589</url>
  </required_header>
  <id_info>
    <org_study_id>HR-IRI-APC</org_study_id>
    <nct_id>NCT05074589</nct_id>
  </id_info>
  <brief_title>Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of irinotecan hydrochloride liposome in combination with&#xD;
      5-FU/LV as second-line treatment for locally advanced or metastatic pancreatic cancer after&#xD;
      treatment failure with gemcitabine-based therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">April 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, single-dummy, parallel-controlled, multicentre study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>The maximum time in follow up was approximately 12 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause, or censored at date last known alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>The maximum time in follow up was 12 months</time_frame>
    <description>Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Assessment every 6 weeks after initial response; maximum time on study 12 months</time_frame>
    <description>Objective response rate was based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>The maximum time in follow up was 12 months</time_frame>
    <description>Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Tumor Marker (CA 19-9) Response</measure>
    <time_frame>Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 12 months</time_frame>
    <description>Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life（QoL）</measure>
    <time_frame>Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 12 months</time_frame>
    <description>QoL was based on EORTC-QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan liposome plus 5-fluorouracil, Leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus 5-fluorouracil, Leucovorin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan liposome、5-Fluorouracil、Leucovorin</intervention_name>
    <description>Irinotecan liposome、5-Fluorouracil、Leucovorin</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo、5-Fluorouracil、Leucovorin</intervention_name>
    <description>Placebo、5-Fluorouracil、Leucovorin</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed pancreatic cancer;&#xD;
&#xD;
          2. Unresectable locally advanced or metastatic disease ;&#xD;
&#xD;
          3. Documented disease progression after first-line treatment gemcitabine based therapy&#xD;
&#xD;
          4. ECOG: 0-1;&#xD;
&#xD;
          5. Adequate organ and bone marrow function;&#xD;
&#xD;
          6. sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active CNS metastasis;&#xD;
&#xD;
          2. Uncontrolled tumor-related pain;&#xD;
&#xD;
          3. Clinically significant GI disorders;&#xD;
&#xD;
          4. Significant cardiovascular disease;&#xD;
&#xD;
          5. Active infection or uncontrolled fever;&#xD;
&#xD;
          6. Pregnant or breast feeding patients;&#xD;
&#xD;
          7. Allergic to a drug ingredient or component;&#xD;
&#xD;
          8. The investigators determined that other conditions were inappropriate for&#xD;
             participation in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

